NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 239 filers reported holding NEKTAR THERAPEUTICS in Q2 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $79,009 | -68.3% | 112,404 | +1.8% | 0.04% | -66.9% |
| Q4 2022 | $249,549 | +8.5% | 110,420 | +53.3% | 0.13% | +41.3% |
| Q3 2022 | $230,000 | -14.8% | 72,018 | +1.5% | 0.09% | -8.0% |
| Q2 2022 | $270,000 | +70.9% | 70,964 | +141.9% | 0.10% | +40.8% |
| Q1 2022 | $158,000 | -60.1% | 29,334 | 0.0% | 0.07% | -52.7% |
| Q4 2021 | $396,000 | -14.8% | 29,334 | +13.4% | 0.15% | -26.8% |
| Q3 2021 | $465,000 | -4.1% | 25,864 | -8.4% | 0.20% | +3.0% |
| Q2 2021 | $485,000 | -31.7% | 28,241 | -20.4% | 0.20% | -33.7% |
| Q1 2021 | $710,000 | +21.0% | 35,476 | +2.8% | 0.30% | +23.0% |
| Q4 2020 | $587,000 | +24.1% | 34,503 | +21.0% | 0.24% | -1.6% |
| Q3 2020 | $473,000 | -21.8% | 28,525 | +9.2% | 0.25% | -13.6% |
| Q2 2020 | $605,000 | +22.5% | 26,122 | -5.6% | 0.29% | +41.4% |
| Q1 2020 | $494,000 | -23.8% | 27,666 | -7.8% | 0.20% | +91.5% |
| Q4 2019 | $648,000 | +71.4% | 30,000 | +44.6% | 0.11% | +39.5% |
| Q3 2019 | $378,000 | -56.6% | 20,742 | -15.2% | 0.08% | -58.5% |
| Q2 2019 | $870,000 | +59.6% | 24,468 | +47.5% | 0.18% | +96.8% |
| Q4 2018 | $545,000 | -35.6% | 16,594 | +19.6% | 0.09% | +6.9% |
| Q3 2018 | $846,000 | +33.9% | 13,877 | +7.2% | 0.09% | -84.4% |
| Q2 2018 | $632,000 | -60.4% | 12,942 | -13.8% | 0.56% | -59.6% |
| Q1 2018 | $1,595,000 | +58.1% | 15,011 | -11.1% | 1.38% | +9.3% |
| Q4 2017 | $1,009,000 | -25.1% | 16,891 | -69.9% | 1.27% | +595.6% |
| Q3 2017 | $1,347,000 | +22.8% | 56,131 | 0.0% | 0.18% | +11.0% |
| Q2 2017 | $1,097,000 | -45.0% | 56,131 | -34.0% | 0.16% | -53.8% |
| Q1 2017 | $1,995,000 | +111.6% | 85,008 | +10.6% | 0.36% | +25.9% |
| Q4 2016 | $943,000 | +32.6% | 76,834 | +85.7% | 0.28% | -18.0% |
| Q3 2016 | $711,000 | +38.3% | 41,365 | +14.4% | 0.34% | -9.7% |
| Q2 2016 | $514,000 | -2.3% | 36,153 | -5.5% | 0.38% | -47.4% |
| Q1 2016 | $526,000 | -18.4% | 38,260 | 0.0% | 0.72% | -59.0% |
| Q4 2015 | $645,000 | – | 38,260 | – | 1.77% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |